CardioBites: Amyloidosis

Amyloidosis (am-uh-loi-DO-sis) is a rare disease that may affect the heart, kidneys, liver, spleen, nervous system and digestive tract. Learn more about this complex and serious condition in the CardioBites Amyloidosis series.

Videos in the Series

What is Amyloidosis
Amyloidosis (am-uh-loi-DO-sis) is a rare disease that may affect the heart, kidneys, liver, spleen, nervous system and digestive tract. Learn more about this complex and serious condition. Watch now

What are the Signs and Symptoms of Amyloidosis?
Amyloidosis (am-uh-loi-DO-sis) is a rare disease that may affect the heart, kidneys, liver, spleen, nervous system and digestive tract. Learn more about this complex and serious condition. Watch now

What are the Most Common Types of Amyloidosis?
Amyloiosis is a rare disease associated with the accumulation of insoluble amyloid fibrils in the body. Join us as we discuss the different types of amyloidosis and how this condition affects the body. Watch now

What Do We Know About the Genetics of Amyloidosis?
Is amyloidosis hereditary? Is genetic screening necessary? In this CardioBites, we explore what we know about the genetics of hereditary and wild-type amyloidosis and who is at risk for these conditions. Watch now

How is Amyloidosis Diagnosed?
Patients with cardiac amyloidosis often have symptoms suggestive of heart failure with preserved ejection fraction (HFPEF). In our fifth Amyloidosis module, learn how to evaluate these symptoms and diagnose cardiac amyloidosis. Watch now

Treatment and Management of Immunoglobulin Light Chain (AL) Amyloidosis
Treatment of patients with immunoglobulin light chain amyloidosis or AL is based on the degree of cardiac involvement and staging. In this video, we examine staging factors, prognosis, and treatment options for these patients. Watch now

Treatment and Management of Transthyretin-mediated (ATTR) Amyloidosis
The management of patients with transthyretin amyloidosis includes 2 main categories of disease-modifying therapies. This video discusses the role of TTR stabilizers and TTR silencers/knockdown agents along with heart failure and arrhythmia management for the management of patients with cardiac ATTR. Watch now

Multidisciplinary Care of Amyloidosis
In this module, we explore how a multidisciplinary care team approach can shorten the time to diagnosis, facilitate effective treatment decisions, and improve the quality of care for patients with amyloidosis. Watch now

Amyloidosis Treatments on the Horizon
The treatment of transthyretin cardiac amyloidosis is evolving rapidly. In this module, we discuss the new and emerging therapies that can better assist patients in reaching their goals and improving health outcomes. Watch now

Subscribe to the HFSA YouTube Channel

Subscribe to the HFSA YouTube Channel.

Supporter(s)

The Heart Failure Society of America acknowledges Alnylam for providing an independent grant to support the HFSA CardioBites: Amyloidosis.

Summary

Cost:

FREE

Credit:

No Credit Offered

Create Account